Baseline and 12-month follow-up clinical and biological characteristics of patients reaching DAS remission and not reaching remission at follow-up
| Characteristics | Baseline characteristics of patients achieving DAS remission (56 patients) | Baseline characteristics of patients not achieving DAS remission (65 patients) | Follow-up characteristics of patients achieving DAS remission (56 patients) | Follow-up characteristics of patients not achieving DAS remission (65 patients) |
|---|---|---|---|---|
| Age, years | 52.1±15.1 | 55.0±11.4 | – | – |
| Sex, no. F (%) | 38 (67.9%) | 54 (83.1%)* | – | – |
| Disease duration, months | 5.6±3.5 | 5.9±3.5 | – | – |
| VERA, n (%) | 21 (37.5%) | 23 (35.4%) | – | – |
| ACPA, U/ml | 81.6±133.7 | 60.6±45.0 | 45.7±39.8 | 43.5±38.4 |
| ACPA+, n (%) | 47 (83.9%) | 41 (63.1%) | 38 (69.1%) | 41 (63.1%) |
| RF-IgM, U/ml | 94.6±115.2 | 92.2±136.3 | 38.9±73.1 | 34.2±47.7 |
| RF-IgM+, n (%) | 38 (67.9%) | 44 (67.7%) | 17 (30.6%) | 21 (32.3%) |
| RF-IgA, U/ml | 165.1±170.1 | 179.5±249.1 | 58.3±114.4 | 33.8±59.7 |
| RF-IgA+, n (%) | 23 (41.1%) | 22 (33.8%) | 11 (20.0%) | 9 (14.1%) |
| ESR, mm/I° h | 31.6±25.0 | 42.0±24.0* | 9.8±6.2 | 20.8±16.7† |
| CRP, mg/litre | 19.7±26.6 | 24.3±32.3 | 2.6±3.6 | 5.6±7.8† |
| DAS44 | 3.0±0.8 | 3.6±0.7* | 1.0±0.4 | 2.2±0.8† |
| HAQ-DI | 1.1±0.7 | 1.4±0.7* | 0.2±0.2 | 0.6±0.6† |
| Erosives | 15 (26.8%) | 19 (29.2%) | 21 (37.5%) | 27 (41.5%) |
| Sharp erosion score | 2.4±2.5 | 2.5±2.2 | 2.4±2.5 | 2.5±2.1 |
| Larsen score | 3.8±2.4 | 4.3±3.3 | 3.6±2.7 | 4.2±3.0 |
Characteristics at baseline and after 12 months of patients reaching DAS remission or not reaching DAS remission after 12 months of follow-up. Values are mean±SD.
↵* p<0.05 between baseline characteristics of patients achieving and not achieving DAS remission.
↵† p<0.05 between 12-month follow-up characteristics of patients achieving and not achieving DAS remission.
ACPA, anti-cyclic citrullinated peptide antibodies; CRP, C reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; RF, rheumatoid factor; VERA, very early rheumatoid arthritis.